Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk
Johnson & Johnson shares rose 0.76% to $220.14 at Friday’s close, outpacing other major pharma stocks. The company reaffirmed its 2026 sales and profit targets after posting Q4 sales of $24.6 billion and adjusted EPS of $2.46. Legal risks remain as a special master recommended expert testimony in federal talc lawsuits. Investors await the Federal Reserve’s rate decision on Wednesday.